.5% versus 7.9%; ertapenem versus ceftriaxone 3.2% versus 4.6%); nausea (ertapenem versus piperacillin-tazobactam 2.5% versus 3.4%; ertapenem versus ceftriaxone 3.4% versus 3.3%); and elevations in alanine aminotransferase levels (ertapenem versus piperacillin-tazobactam 8.8% versus 7.3%; ertapenem versus ceftriaxone 8.3% versus 6.9%). Most ertapenem-related AEs were reported as mild-to-moderate in intensity. Ertapenem was not associated with prolongation of the QTc interval. Local reactions of moderate-to-severe intensity at the infusion site were infrequent and occurred with similar frequency in the ertapenem and comparator treatment groups. No overall differences in safety were observed between elderly (aged ≥65 years and ≥75 years) and younger patients. Ertapenem, 1 g once a day given by intravenous infusion or intramuscular injection, was generally well tolerated and had overall safety and tolerability profiles similar to those of piperacillin-tazobactam and ceftriaxone.
Introduction
Ertapenem (formerly MK-0826; Merck & Co., Inc.) is a parenteral β-lactam antimicrobial agent that was licensed in the USA in November 2001 and in Europe in April 2002. This Group 1 carbapenem 1 has a focused spectrum of activity-ertapenem is highly active in vitro against bacteria that are generally associated with community-acquired and mixed aerobic/anaerobic infections, including methicillinsusceptible Staphylococcus aureus and many Haemophilus spp., streptococci, Enterobacteriaceae and anaerobes, but has limited activity against non-fermentative Gram-negative bacilli, methicillinresistant S. aureus or enterococci, which are more often associated with nosocomial infection. [2] [3] [4] In large, randomized clinical trials ertapenem, 1 g once a day, was as effective as piperacillintazobactam, 3 .375 g every 6 h, for the treatment of complicated intra-abdominal, complicated skin/skin-structure and acute pelvic infections, and as effective as ceftriaxone, 1 g once a day, for the treatment of complicated urinary tract infections (UTIs) and communityacquired pneumonia (CAP). [5] [6] [7] [8] [9] The purpose of this report is to review the safety and tolerability profiles of ertapenem and compare them with those of ceftriaxone and piperacillin-tazobactam, the comparator agents used in the clinical trials.
Patients and methods
The population included in this report consists of (i) 240 healthy adult volunteers enrolled in 12 Phase I clinical pharmacology studies, and (ii) 2046 adult patients enrolled in five randomized, double-blind Phase IIa trials, seven randomized, double-blind (with sponsor blinding) Phase IIb/ III trials assessing the safety and efficacy of ertapenem in the treatment of complicated intra-abdominal infection (IAI), complicated skin/skinstructure infection, complicated UTI, acute pelvic infection, or CAP or other lower respiratory tract infection, and one double-blind (with sponsor blinding) Phase IIb trial assessing the safety and tolerability of intramuscular (im) ertapenem reconstituted in 1% lidocaine without epinephrine. 10 In the Phase I clinical pharmacology studies, ertapenem was administered intravenously (iv) or im once a day at doses of <1, 1, 1.5, 2 and 3 g. Intravenous doses of ≤2 g were infused over 30 min. The infusion duration of the 3 g iv dose initially was 1 h, but this was changed to 2 h due to the apparent association of nausea with the more rapid infusion rate. In a QTc interval study, healthy volunteers received a single 2 g iv dose of ii76 ertapenem. Early in the development programme, ertapenem doses of 1, 1.5 and 2 g, each once a day, were examined in a limited number of patients in the IAI and CAP clinical trials. Owing to the comparable efficacy of these dosages in these early clinical trials, the dose of 1 g once a day was evaluated in the pivotal Phase IIb/III ertapenem clinical trials, and was shown to be highly effective. For patients with severe renal insufficiency (creatinine clearance <1.8 L/h/1.73 m 2 ) not requiring dialysis in the Phase IIb and Phase III skin, CAP, UTI and pelvic infection trials, the dose of ertapenem was 500 mg once a day; such patients were excluded from all other Phase II and Phase III trials. Comparator agents were ceftriaxone 1 g iv or im once a day (Phase IIa, CAP, UTI and im tolerability trials) or iv piperacillin-tazobactam 3.375 g every 6 h (Phase IIb/III IAI, skin and pelvic infection trials). The dose of piperacillintazobactam was adjusted as recommended in the product circular in patients with severe renal insufficiency. Patients in several Phase IIa trials and a limited number of patients in Phase IIb/III CAP trials received ceftriaxone 2 g once a day. For the trials in which ceftriaxone was the comparator, patients received one infusion of study drug and one infusion of colour-matched placebo each day; when piperacillin-tazobactam was the comparator, patients in the ertapenem group also received subsequent placebo infusions of normal saline every 6 h. Patients in the comparator arm of the Phase IIa IAI trial received iv metronidazole 500 mg every 8 h as well as iv ceftriaxone. In all Phase IIa trials and the Phase IIb/III CAP, UTI and im tolerability trials, investigators had the option to switch patients who clinically improved after ≥3 days of parenteral therapy (2 days for the im tolerability study) to an appropriate oral agent (co-amoxiclav or ciprofloxacin were recommended; in the Phase IIa IAI trial, patients were switched to oral ciprofloxacin plus oral metronidazole).
In the Phase I-III trials, healthy volunteers and patients who received one or more doses of the study drug were evaluated for safety and were monitored for adverse events (AEs) daily during study therapy (parenteral plus optional oral) and for 14 days after the last dose. The investigator categorized the intensity of each clinical AE (mild, moderate or severe) and for both clinical and laboratory AEs assessed the likelihood of a causal relationship to the study drug (definitely not, probably not, possibly, probably or definitely). A drug-related AE was one that the investigator considered to be possibly, probably or definitely related to the study drug. Certain AEs were considered to be serious (i.e. any that resulted in death, persistent or significant disability, or hospitalization, was life-threatening in the opinion of the investigator, prolonged existing hospitalization or was associated with a congenital anomaly). Other medical events requiring medical or surgical intervention were designated serious at the discretion of the investigator. The tolerability of each study drug at the infusion site was evaluated daily by the investigator. At the discretion of the investigator, a local reaction may also have been reported as an AE. Only drug-related AEs are discussed in this report, unless otherwise stated.
Results

Clinical pharmacology trials
In the ertapenem Phase I clinical pharmacology studies, 41 healthy volunteers received one or more doses of <1 g, 149 volunteers received one or more doses of 1 g, six volunteers received a single 1.5 g dose, 62 volunteers received one or more doses of 2 g and 29 volunteers received one or more doses of 3 g. Some volunteers received different doses. The most common clinical AEs among these subjects were diarrhoea, nausea and headache, and the most common laboratory AE was mild elevation of alanine aminotransferase. All AEs were transient and of mild-to-moderate intensity; none appeared to be dose related. Ertapenem was discontinued due to an AE in 10 (4.5%) volunteers; reasons for discontinuation were rash in three volunteers, diarrhoea in two volunteers, urticaria, folliculitis and reflux oesophagitis in one volunteer, nausea and dizziness in one volunteer each, and diarrhoea, vomiting, nausea, dizziness, sweating and paraesthesia in one volunteer. In three Phase I trials that assessed im tolerability, five (8.8%) of the 57 healthy volunteers who received ertapenem 1 g once a day for ≥1 days had symptoms of mild-tomoderate intensity at the im injection site. No patient experienced local symptoms of severe intensity.
In the QTc study, there was no statistically significant change from baseline in the mean values for QTc interval at 30 min and 1.5 h post-dose in the 20 volunteers who received ertapenem 2 g or the four who received normal saline placebo (Table 1) . Using manually determined or machine-calculated QTc interval determinations, criteria for prolongation (of a concerning degree) of the QTc interval (i.e. increase ≥60 ms over baseline or an absolute QTc interval >450 ms in males or >470 ms in females) were not met at 30 min or 1.5 h after the start of infusion in any subject. Safety profile. In the Phase II and Phase III trials, 1954 patients received one or more doses of ertapenem 1 g, 62 patients received one or more doses of ertapenem 1.5 g, 30 patients received one or more doses of ertapenem 2 g, 774 patients received one or more doses of piperacillin-tazobactam 3.375 g and 942 patients received one or more doses of ceftriaxone 1 or 2 g. The pattern and frequency of AEs that were reported in patients who received 1.5 or 2 g of ertapenem were similar to those reported in patients who received 1 g of ertapenem. Therefore, the AE profile of the recommended ertapenem 1 g dose only is described here. The demographics of patients enrolled in the Phase II and Phase III trials, and treatment duration are shown in Table 2 . In this treated population, one or more clinical AEs were reported during study therapy (parenteral plus optional oral) and for 14 days after the last dose for 454 (23.2%) of 1954 patients in the ertapenem group, 180 (23.3%) of 774 patients in the piperacillin-tazobactam group and 253 (26.9%) of 942 patients in the ceftriaxone group. Clinical AEs (both drug related and those reported irrespective of relationship to study drug therapy) occurring with a frequency of ≥1% in any treatment group are shown in Table 3 . Of the AEs, 21 (1.1%), two (0.3%) and five (0.5%) in the ertapenem, piperacillin-tazobactam and ceftriaxone groups, respectively (most commonly diarrhoea, seizure and confusion), were considered by the investigator to be serious. In all treatment groups, gastrointestinal (GI) disturbances were the most common AEs, followed by infused vein complications. The incidence of pseudomembranous colitis and Clostridium difficileassociated diarrhoea was low during parenteral ertapenem therapy [6/1866 patients (0.3%)] and similarly low in the comparator groups. Three (0.2%) patients in the ertapenem group, two (0.3%) patients in the piperacillin-tazobactam group and none in the ceftriaxone group experienced a seizure during parenteral therapy that was considered to be drug related. Three of these five patients had underlying neurological disease, and two patients had a pre-existing seizure disorder. During study therapy plus the 14 day follow-up period, seizures were reported in an additional seven patients in the ertapenem group; none was considered drug related and all occurred ≥2 days after the end of study therapy. Study parenteral therapy was discontinued due to a clinical AE in 24 (1.2%) patients who received ertapenem, 12 (1.6%) patients who received piperacillin-tazobactam and six (0.6%) patients who received ceftriaxone. The most common reasons for discontinuation of study therapy were GI disturbances (ertapenem and ceftriaxone) and rash (ertapenem and piperacillin-tazobactam).
One or more laboratory AEs were reported during study therapy (parenteral plus optional oral) and for 14 days after the last dose in 260 (13.8%) of 1888 patients in the ertapenem group, 113 (15.0%) of 755 patients in the piperacillin-tazobactam group and 106 (11.5%) of 920 patients in the ceftriaxone group. Laboratory AEs (both drug related and those reported irrespective of relationship to study drug therapy) occurring with a frequency of ≥1% among >100 patients in any treatment group are shown in Table 4 . In all treatment groups, the most common AE was a transient, mild-to-moderate elevation in aminotransferase levels, which rarely exceeded five times the upper limit of normal. In all patients for whom information was available, enzyme levels had returned to normal or near-normal levels at follow-up testing. Drug-related neutropenia was reported infrequently in all treatment groups. Of the 16 patients in the ertapenem group for whom neutropenia was considered to be drug related, none had study therapy discontinued. The absolute neutrophil count was ii78 <1000 cells/mm 3 in only two of the 16 patients, both of whom had a decreased total white blood cell count at study enrolment and were receiving several concomitant medications. In both patients, the absolute neutrophil count had risen to >1000 cells/mm 3 on the subsequent test date. Study parenteral therapy was discontinued due to a drug-related laboratory AE in three (0.2%) patients treated with ertapenem, three (0.4%) patients treated with piperacillin-tazobactam and one (0.1%) patient treated with ceftriaxone. During study therapy plus the 14 day follow-up period there were 34 (1.8%) deaths in the ertapenem group, 12 (1.5%) in the piperacillin-tazobactam group and 15 (1.6%) in the ceftriaxone group. Deaths were considered unrelated to study drugs by investigators. Mortality varied in the different trials and was highest in the Phase IIb IAI study, which may have been related to the severity of the underlying disease. Fifteen (4.7%) of 316 patients in the ertapenem 1 g group of the Phase IIb IAI study and eight (2.6%) of 307 patients in the piperacillin-tazobactam group died during study therapy plus the 14 day follow-up period. All these patients had significant underlying comorbid conditions and/or severe baseline infections.
Local tolerability. During the iv therapy period of Phase IIb and
Phase III trials, 138 (7.9%) of 1743 patients in the ertapenem group, 66 (8.5%) of 774 patients in the piperacillin-tazobactam group and 55 (7.3%) of 750 patients in the ceftriaxone group experienced moderate-to-severe symptoms at the infusion site, most commonly pain, followed by tenderness, local phlebitis, erythema and induration. With regard to im tolerability, 31 (27.9%) of 111 patients in the ertapenem group and 14 (33.3%) of 42 patients in the ceftriaxone group experienced one or more symptoms at the local injection site; symptoms were of moderate-to-severe intensity in one (0.9%) patient who received ertapenem and four (9.5%) patients who received ceftriaxone. 10 
Drug-disease, drug-drug and drug-demographic interactions
Safety data (total therapy plus 14 days) from Phase IIb and Phase III clinical trials were reviewed to assess possible differences based on index infection or the presence of renal dysfunction, and to assess possible interactions between study drugs and other commonly used classes of drug (antiarrhythmics, anticonvulsants, digitalis, lithium, oral hypoglycaemics, xanthines), gender, ethnic group or age. Phase IIb and Phase III data were used for this examination to focus on treatment groups of similar size and the recommended ertapenem 1 g dose. No important differences in overall AE profile, regardless of relationship to study therapy, were identified for any of the study drugs based on renal dysfunction or receipt of concomitant therapy (data not shown). The proportion of patients who had one or more clinical and/or laboratory AEs and the pattern of specific AEs were generally similar for both genders in the three treatment groups (data not shown). 11 The AE profiles of ertapenem and comparator drugs were also similar across ethnic groups (data not shown), with two exceptions. In all treatment groups, the proportion with infused vein complications was lower in white, black and Hispanic patients than in other ethnic groups (including Mestizo, Asian, Mexican, Indian, Hawaiian, Spanish American and mixed, among others) combined; and the frequency of aminotransferase elevation was highest for Hispanic patients, lowest for black patients and between the two extremes for white patients. 12 The fact that these trends occurred in all treatment groups suggests that the differences reflected reporting variability or other baseline factors rather than a treatment effect. The frequency of aminotransferase elevation was highest among patients with IAI; most probably a reflection of the primary site of infection.
Because some of the physiological changes that occur with advancing age may affect the absorption, distribution, metabolism and elimination of antimicrobial agents 13 and, therefore, theoretically could affect the AE profile of ertapenem, safety was examined in more depth in elderly patients in the Phase IIb and Phase III clinical trials. Nine hundred and eight (26.8%) patients in these trials were aged ≥65 years. The proportions of white patients and males were higher and the proportions of black and Hispanic patients (except for the ceftriaxone group), and other racial groups were lower in patients aged ≥65 years than in those who were younger (Table 5 ). Gender and treatment duration were generally similar for both age groups (Table  5 ). In the <65 years age group, one or more clinical AEs were reported during study therapy (parenteral plus optional oral) and the 14 day follow-up period for 327 (24.2%) of 1353 patients in the ertapenem group, 135 (21.1%) of 639 patients in the piperacillin-tazobactam group and 134 (27.3%) of 490 patients in the ceftriaxone group; and one or more laboratory AEs were reported for 188 (14.4%) of 1305 patients in the ertapenem group, 97 (15.6%) of 623 patients in the piperacillin-tazobactam group and 64 (13.4%) of 478 patients in the ceftriaxone group. In those aged ≥65 years, one or more clinical AEs were reported during the same time period for 95 (19.7%) of 482 patients in the ertapenem group, 45 (33.3%) of 135 patients in the piperacillin-tazobactam group and 71 (24.4%) of 291 patients in the ceftriaxone group; laboratory AEs were reported for 62 (13.3%) of 466 patients, 16 (12.1%) of 132 patients and 32 (11.3%) of 283 patients in the ertapenem, piperacillin-tazobactam and ceftriaxone groups, respectively. The pattern of specific AEs was generally similar for the three treatment groups in patients aged <65 years and those aged ≥65 years (Table 6) , with minor exceptions. Diarrhoea occurred more frequently in patients aged ≥65 years, particularly in patients who received piperacillin-tazobactam, whereas headache and elevated aminotransferase concentrations tended to occur more frequently in patients aged <65 years (in all treatment groups). The AE profiles for ertapenem and the comparator drugs in patients aged <75 years and those aged ≥75 years [n = 431 (12.7%) patients] were generally similar to the profiles in the <65 years and ≥65 years age groups (data not shown).
Discussion
The safety and tolerability of ertapenem have been evaluated in 240 healthy adult volunteers and >2000 adult patients with acute bacterial infections. Data from the clinical pharmacology studies showed no dose relationship for clinical or laboratory AEs associated with iv or im ertapenem at doses of <1-3 g and no clinically significant prolongation of the QTc interval following iv administration of 2 g ertapenem. In addition, no dose relationship was demonstrated in the Phase II and III clinical trials. The incidence of most clinical and laboratory AEs was similar between ertapenem 1 g and the comparator agents, piperacillintazobactam and ceftriaxone. The rates of serious AEs and discontinuations due to an AE associated with ertapenem were also low and generally similar to those due to the comparators. Diarrhoea was the most frequently reported clinical AE in all the treatment groups, but the incidence of C. difficile-associated disease was very low. The most common laboratory AE associated with ertapenem and both comparator agents was mild-to-moderate elevation of aminotransferase levels, which tended to be transient, returning to normal or near-normal levels by the time follow-up testing was performed, and without clinical consequence. In all treatment groups, aminotransferase elevation was more common among Hispanic patients than among white or black patients. The reason for this difference is unknown.
Drug-related neutropenia was infrequent and, when it occurred, almost always mild and transient; it was rarely a cause for discontinuation of study therapy and, therefore, was probably of minor clinical importance. Neutropenia is a known but uncommon complication of therapy with β-lactam agents, is generally associated with high doses and prolonged therapy, and is reversible when the drug is discontinued. [14] [15] [16] Amongst those treated with ertapenem in the trials reported here, only two patients, both of whom had a decreased total white blood cell count at study entry, experienced a drop in neutrophil count (to <1000 cells/mm 3 ) on at least one occasion. In both of these patients, absolute neutrophil counts were rising at times of follow-up testing.
Seizures have been associated with meropenem and imipenem. [17] [18] [19] [20] In the clinical trials reported here, seizures in patients treated with ertapenem 1 g were rare, irrespective of drug relationship (0.5% during study therapy plus the 14 day follow-up period, versus 0.3% for piperacillin-tazobactam), and almost all patients who experienced a seizure had underlying central nervous system disease or a known seizure disorder. The incidence during parenteral therapy of seizures considered to be drug related in patients who received ertapenem therapy (0.2%) was similar to the incidence in patients in these trials who were treated with piperacillin-tazobactam (0.3%).
No important differences from the overall ertapenem AE profile were identified based on index infection, renal dysfunction, receipt of concomitant therapy or gender. Although elevations in aminotransferase levels were more frequent in Hispanics than all other ethnic groups, the fact that this trend occurred in all treatment groups Table 6 . Clinical and laboratory adverse events (AEs) occurring with a frequency of ≥2% during study therapy (parenteral plus optional oral) and for 14 days thereafter in patients in the ertapenem (ETP), piperacillin-tazobactam (P/T) or ceftriaxone (CRO) treatment groups of the Phase IIb and Phase III trials, by age n, number of patients who experienced an AE; m, number of patients who had one or more laboratory tests performed after study entry; ALT, alanine transaminase; AST, aspartate transaminase. a Considered by the investigator to be possibly, probably or definitely related to study drug therapy. b Denominator is females. ii81 suggests that the difference was not drug related. Therapy with ertapenem did not appear to be associated with any increased risk of AEs in the elderly (aged ≥65 years or ≥75 years). In fact, the frequency of AEs was slightly lower in patients aged ≥65 years than in those <65 years of age. In summary, ertapenem, administered iv or im, was generally well tolerated in healthy adult volunteers and in elderly and non-elderly patients with acute bacterial community-acquired and mixed aerobic/anaerobic infections. AEs associated with ertapenem therapy were generally transient, and most were of mild-to-moderate severity, infrequently resulting in discontinuation of the drug. The overall safety and tolerability profiles of ertapenem were comparable to those of piperacillin-tazobactam and ceftriaxone.
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